'Greg' Works In The Compounding Industry On Copycat Ozempic Crackdown

Greg (not using his last name) is a Regional Director for a broker in the compounding industry. He heard me talking about the FDA's ruling that there is no longer a shortage of the main ingredients in Ozempic and Wegovy and therefore compounding pharmacies won't be allowed to make cheaper versions of those drugs starting in about two months. Greg believes the pharmacies will keep making the "copycat" medicines.

Copycat Ozempic makers brace for crackdown


View Full Site